If I reference the IOM report again here, in the United States, use of clinical data in the regulatory review process is defined by the enabling legislation, regulations and FDA's implementation of the legislation and regulations.
Senator Hagan discusses the role of clinical data in regulatory review.
Share
More from Kay Hagan
I ask unanimous consent that the Committee on Intelligence be authorized to meet during the session of the Senate on July 10, 2014, at 2:30 p.m. The PRESIDING OFFICER. Without objection, it is so ordered. ____________________
I hate to bring this hearing to a close, but I do thank all of you for your testimony.
I have heard a number of concerns from communities in North Carolina about the exclusion of the municipal securities from the high-quality liquid assets designation.
I ask unanimous consent that the Committee on the Judiciary be authorized to meet during the session of the Senate on July 10, 2014, at 9:30 a.m., in room SD-226 of the Dirksen Senate Office Building, to conduct an executive business…
Other voices in this conversation
